Form 4: Apyx Medical Corp CFO Matthew C. Hill Granted Stock Options

Apyx Medical Corp's CFO, Matthew C. Hill, was granted stock options on January 15, 2025, according to a Form 4 filing with the SEC.

Summary

• Matthew C. Hill, the Chief Financial Officer of Apyx Medical Corp, was granted stock options on January 15, 2025.
• The stock option allows him to buy 50,000 shares of Apyx Medical Corp stock at an exercise price of $1.42 per share.
• The options vest ratably over a 36-month period and will be fully vested and exercisable on January 15, 2028.
• Following the transaction, Hill directly owns options for 50,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a common practice.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock options are a common form of executive compensation in the medical device industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The vesting schedule of 36 months is a typical vesting period for stock options.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its relative value.

Stakeholder Impact

• The stock option grant could potentially incentivize the CFO to improve company performance, benefiting shareholders.

Key Dates